INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27301, 28087, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27302, 28088, 'Tetracycline', 'Esophageal Diseases', 'The use of oral tetracycline capsules and tablets has been associated with esophageal irritation and ulceration in patients who ingested the drug without sufficient fluid shortly before bedtime.  Therapy with solid formulations of tetracyclines should preferably be avoided in patients with esophageal obstruction, compression or dyskinesia.  If the drugs are used, patients should be advised not to take the medication just before retiring and to drink fluids liberally.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27303, 7196, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27304, 11072, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27305, 11073, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27306, 14146, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27307, 20022, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27308, 28077, 'Testosterone', 'Prostatic Neoplasms', 'The use of androgenic anabolic steroids is contraindicated for male patients with carcinoma of the breast or prostate.  Circulating androgens can be converted in peripheral tissues to estrogens and dihydrotestosterone, which may act as promoters of tumor growth in the breast and prostate, respectively.  Likewise, androgenic agents may cause enlargement of the prostate and should be used cautiously in patients with or predisposed to prostatic hypertrophy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27309, 7196, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27310, 11072, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27311, 11073, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27312, 14146, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27313, 20022, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27314, 28077, 'Testosterone', 'Water-Electrolyte Imbalance', 'Androgenic anabolic steroids may cause sodium and water retention, particularly when given in high dosages or for prolonged periods.  Therapy with these agents should be administered cautiously in patients who have preexisting problems with fluid overload or are at risk for developing edema.  The manufacturers consider the use of androgenic agents to be contraindicated in patients with severe cardiac, renal and/or hepatic dysfunction.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27315, 7196, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27316, 11072, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27317, 11073, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27318, 14146, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27319, 20022, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27320, 28077, 'Testosterone', 'Breast Neoplasms', 'When treated with androgenic anabolic steroids, patients with metastatic breast cancer may develop hypercalcemia due to osteolysis.  Frequent determination of urine and serum calcium levels is recommended during therapy with androgenic agents.  If hypercalcemia occurs, therapy should be stopped.  The development of hypercalcemia may indicate progression of metastases to the bone.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27321, 7196, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27322, 11072, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27323, 11073, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27324, 14146, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27325, 20022, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27326, 28077, 'Testosterone', 'Hyperlipoproteinemias', 'Androgenic anabolic steroids may adversely affect serum lipids, including lowering HDL and elevating LDL levels.  These changes can be marked, particularly with the 17-alpha-alkyl derivatives (i.e., fluoxymesterone, methyltestosterone, oxandrolone, oxymetholone, and stanozolol), and may significantly impact the risk of atherosclerosis and coronary artery disease.  Patients with preexisting hyperlipoproteinemia may require closer monitoring during therapy with androgenic agents, and adjustments made accordingly in their lipid-lowering regimen.  Androgen therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27327, 7196, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27328, 11072, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27329, 11073, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27330, 14146, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27331, 20022, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27332, 28077, 'Testosterone', 'Liver Diseases', 'The use of androgenic anabolic steroids may be associated with development of cholestatic hepatitis and jaundice.  Other, more serious hepatotoxicities such as peliosis hepatis and hepatocellular neoplasms are rare but may occur with prolonged use or high dosages.  These latter toxicities may be fatal and often not recognized until they become life-threatening.  Patients with preexisting liver diseases should be monitored more closely during therapy with anabolic steroids if they are used.  If liver function declines or toxicity occurs, therapy should be withdrawn and the cause investigated.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27333, 7196, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27334, 11072, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27335, 11073, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27336, 14146, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27337, 20022, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27338, 28077, 'Testosterone', 'Polycythemia', 'Androgenic anabolic steroids may cause polycythemia when given in high dosages or for prolonged periods.  Patients with preexisting polycythemia may experience worsening of their condition.  Frequent monitoring of clinical status and hemoglobin and hematocrit levels is recommended if androgen therapy is administered to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27339, 7196, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27340, 11072, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27341, 11073, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27342, 14146, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27343, 20022, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27344, 28077, 'Testosterone', 'Blood Coagulation Disorders', 'Androgenic anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.  Androgen therapy should be administered cautiously in patients with bleeding disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27345, 7196, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27346, 11072, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27347, 11073, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27348, 14146, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27349, 20022, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27350, 28077, 'Testosterone', 'Diabetes Mellitus', 'The metabolic effects of androgenic anabolic steroids may lower blood glucose.  Decreased glucose tolerance and increased insulin resistance have also been reported.  Patients with diabetes mellitus should be monitored more closely during therapy with androgenic agents, and their antidiabetic regimen adjusted accordingly.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27351, 7196, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27352, 11072, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27353, 11073, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27354, 14146, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27355, 20022, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27356, 28077, 'Testosterone', 'Hypercalcemia', 'Androgenic anabolic steroids decrease urinary excretion of calcium, which may result in hypercalcemia.  Therapy with androgenic agents should be administered cautiously in patients with hypercalcemia, disorders of bone metabolism such as hyperparathyroidism, or renal dysfunction.  Some manufacturers consider the use of androgenic anabolic steroids to be contraindicated in patients with hypercalcemia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27357, 7196, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27358, 11072, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27359, 11073, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27360, 14146, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27361, 20022, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27362, 28077, 'Testosterone', 'Thyroid Diseases', 'When androgenic anabolic steroids are used in patients with thyroid disorders, clinicians should be aware that these agents may affect thyroid function tests.  Specifically, thyroid-binding globulin levels may be decreased, resulting in lower total T4 serum levels and increased resin uptake of T3 and T4.  Free thyroid hormone levels remain unchanged, however.', '1', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27363, 0, 'Tetrabenazine', 'Arrhythmias, Cardiac', 'Tetrabenazine can cause an increase in the corrected QT interval.  QT prolongation can lead to the development of ventricular arrhythmias.  The use of tetrabenazine should be avoided in patients with congenital long QT syndrome and in patients with a history of arrhythmias.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27364, 0, 'Tetrabenazine', 'Depressive Disorder', 'The use of tetrabenazine is contraindicated in patients with untreated or uncontrolled depression.  Tetrabenazine can increase the risk of depression and suicidal thoughts and behavior.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27365, 0, 'Tetrabenazine', 'Hepatic Insufficiency', 'The use of tetrabenazine is contraindicated in patients with hepatic impairment.  The safety and efficacy of exposure to the drug and other metabolites are unknown and it is not possible to adjust the dosage in hepatic impairment to ensure safe use.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27366, 0, 'Tetrabenazine', 'Huntington Disease', 'Patients with Huntington disease are prone to depression.  Tetrabenazine can increase the risk of depression and suicidal thoughts and should be used with caution in patients with Huntington''s disease.  The benefits and risks of treatment should be considered before starting therapy, and patients should be under close observation for emergence or worsening of depression symptoms.  The family and caregivers should also be informed of this risk and should be instructed to report any changes in behavior or any concerns to the treating physician.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27367, 0, 'Tetrabenazine', 'Deglutition Disorders', 'Tetrabenazine reduces dopaminergic transmission and can be associated with esophageal dysmotility and dysphagia.  Caution should be exercised when used in patients with conditions that predispose to dysphagia.  Special caution is advised in patients with Huntington''s disease as dysphagia is a common symptom and it could lead to aspiration pneumonia.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27368, 0, 'Tetrabenazine', 'Hyperprolactinemia', 'Tetrabenazine can elevate serum prolactin concentrations.  This should be considered when therapy will be prescribed in patients with previously detected breast cancer.  Additionally, chronic increase in serum prolactin has been associated with low levels of estrogen and increase risk of osteoporosis.  If there is suspicion of hyperprolactinemia, appropriate laboratory testing is advised and treatment discontinuation should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27369, 0, 'Tetrabenazine', 'Hypotension', 'Tetrabenazine can induce postural dizziness and syncope and should be used with caution in patients who are vulnerable to hypotension.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27370, 0, 'Tesamorelin', 'Pituitary Neoplasms', 'The use of tesamorelin is contraindicated in patients with disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma and in patients with active malignancy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27371, 0, 'Tesamorelin', 'Diabetes Mellitus', 'The use of tesamorelin can result in glucose intolerance.  Tesamorelin increases insulin-like growth factor-1 (IGF-1).  It is recommended to evaluate glucose status prior to initiation of therapy and to monitor periodically during treatment.  Therapy discontinuation may be considered in patients that do not show a clear efficacy response and develop glucose intolerance or diabetes.  Diabetes patients should be monitored for potential development or worsening of retinopathy.  Care should be exercised when using this agent in patients with diabetes.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27372, 0, 'Tesamorelin', 'Water-Electrolyte Imbalance', 'The use of tesamorelin may cause fluid retention related to the induction of growth hormone secretion.  This manifests as increased tissue turgor and musculoskeletal discomfort resulting in adverse reactions (e.g.  edema, arthralgia, and carpal tunnel syndrome) which are either transient or resolve with discontinuation of treatment.  Care should be exercised when using tesamorelin in patients at risks for fluid retention.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27373, 5201, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27374, 5208, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27375, 5209, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27376, 5210, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27377, 5211, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27378, 5293, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27379, 5646, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27380, 7078, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27381, 7079, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27382, 7081, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27383, 7082, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27384, 7086, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27385, 11287, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27386, 11289, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27387, 13902, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27388, 21568, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27389, 21569, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27390, 21572, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27391, 21574, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27392, 23151, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27393, 23153, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27394, 28052, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27395, 28053, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27396, 28054, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27397, 28056, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27398, 28057, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27399, 28058, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (27400, 28060, 'Terbinafine', 'Liver Diseases', 'Oral terbinafine is not recommended for use in patients with chronic or active liver disease.  Terbinafine may be hepatotoxic.  Rare cases of cholestatic hepatitis and liver failure, some resulting in liver transplant or death, have been reported during treatment of various dermatologic conditions in patients with and without preexisting liver disease.  Although a causal relationship has not been established, the severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease.', '3', '', 'DDInter', 0);
